← Leaderboards
Marina Cuchel
University Of Pennsylvania
$7,792,390
Attributed
$7,792,390
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,751,684 · 4
FDA$1,040,706 · 1
By mechanism
R01$4,002,276 · 2
P01$2,726,607 · 1
K23$661,941 · 1
R21$401,566 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Daniel James Rader$77,348,993
- Irena Levitan$11,662,081
- Kiran Musunuru$21,648,838
- James M Wilson$22,532,723
- Raymond R Townsend$20,694,480
Others in their field
Top investigators on “Cholesterol”
- Leon J Thal · University Of California San Diego$54,467,813
- Daniel James Rader · University Of Pennsylvania$44,733,174
- Alan Richard Tall · Columbia University Health Sciences$38,760,184
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$38,718,698
- Ronald M Krauss · University Of Calif-Lawrenc Berkeley Lab$34,107,220
- Stanley L Hazen · Cleveland Clinic Foundation$28,886,562
Research focus
CholesterolClinical TrialsLipidsPhenotypeLiverLipoproteinsMutationBaseIn VivoLow-Density LipoproteinsPre-ClinicalLoss Of Function MutationGene ExpressionApolipoproteins BMouse ModelSafetyHepaticHigh Density LipoproteinsBlood CirculationAtherosclerosisLaboratoriesDesignAffectMetabolism
Grant awards (18)
Trial readiness for LCAT deficiency$401,566
R21 · FY2025 · TR · contact PI
Physiological and therapeutic effects of ANGPTL3 variants in mice and humans$748,107
R01 · FY2022 · HL · contact PI
Physiological and therapeutic effects of ANGPTL3 variants in mice and humans$772,302
R01 · FY2021 · HL · contact PI
Physiological and therapeutic effects of ANGPTL3 variants in mice and humans$767,297
R01 · FY2020 · HL · contact PI
Physiological and therapeutic effects of ANGPTL3 variants in mice and humans$673,864
R01 · FY2019 · HL · contact PI
Project 1 - Clinical Development of Gene Therapy for FH and LCAT Deficiency$545,319
P01 · FY2019 · HL · contact PI
Project 1 - Clinical Development of Gene Therapy for FH and LCAT Deficiency$545,322
P01 · FY2018 · HL · contact PI
Project 1 - Clinical Development of Gene Therapy for FH and LCAT Deficiency$545,322
P01 · FY2017 · HL · contact PI
Project 1 - Clinical Development of Gene Therapy for FH and LCAT Deficiency$545,322
P01 · FY2016 · HL · contact PI
Project 1 - Clinical Development of Gene Therapy for FH and LCAT Deficiency$545,322
P01 · FY2015 · HL · contact PI
MPT INHIBITOR IND 50,820 IN FAMILIAL HYPERCHOLESTEROLEM*$346,687
R01 · FY2009 · FD · contact PI
MPT INHIBITOR IND 50,820 IN FAMILIAL HYPERCHOLESTEROLEM*$347,332
R01 · FY2008 · FD · contact PI
Mechanistic study of CHD risk in subjects with high HDLC$133,017
K23 · FY2008 · HL · contact PI
Mechanistic study of CHD risk in subjects with high HDLC$133,016
K23 · FY2007 · HL · contact PI
MPT INHIBITOR IND 50,820 IN FAMILIAL HYPERCHOLESTEROLEM*$346,687
R01 · FY2006 · FD · contact PI
Mechanistic study of CHD risk in subjects with high HDLC$133,016
K23 · FY2006 · HL · contact PI
Mechanistic study of CHD risk in subjects with high HDLC$132,993
K23 · FY2005 · HL
Mechanistic study of CHD risk in subjects with high HDLC$129,899
K23 · FY2004 · HL